treatment group – Page 11 – Communicable Diseases Research

Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial

Pharmacology

Published on 2021-05-282022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis

COVID-19 환자를 위한 Tocilizumab 치료: 체계적인 검토 및 메타 분석

Review

Published on 2021-05-182022-09-12
Journal: Infectious Diseases of Poverty [Category] 진단,

[키워드] 95% CI Abstract analyses Analysis analyzed Care Clinical outcome conducted confidential interval coronavirus disease Coronavirus disease 2019 correlation COVID-19 COVID-19 patient COVID-19 patients critical cases Cytokine storm database Effect effective Effectiveness estimate Evidence evidence of hazard ratio IL-6 intensive care less lower risk lower risk of mortality management manuscript mechanical ventilation Meta-analysis Mortality overall mortality Patient patients predict Prognosis provide reducing mortality reduction searched Severe case severe cases Significant standard care group stratified supplementary material survival systematic review therapeutic therapy Tocilizumab Treatment treatment for COVID-19 treatment group
[DOI] 10.1186/s40249-021-00857-w PMC 바로가기 [Article Type] Review

Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis

Review Article

Published on 2021-05-062022-10-29
Journal: Interdisciplinary Perspectives on Infectious Diseases [Category] COVID-19,

Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial

Randomized Controlled Trial

Published on 2021-05-012022-10-05
Journal: The Journal of international medical research [Category] SARS, 임상,

[키워드] 95% confidence interval age assigned blinded clinical recovery Combination COVID-19 COVID-19 infection COVID-19 negative COVID-19 symptom disease Disease progression doxycycline Dryad enrolled evaluated Follow-up groups hazard ratio Infection Ivermectin less Median recovery time men Mild-to-moderate outcome Patient patients Placebo placebo group placebo-controlled trial polymerase chain positive Primary outcome proportion Randomized randomized trial Randomly Recovery time reduced remained Repository reverse transcription reverse transcription polymerase chain reaction RT-PCR screened secondary significantly lower the placebo group treated treating COVID-19 Treatment treatment group with COVID-19
[DOI] 10.1177/03000605211013550 PMC 바로가기 [Article Type] Randomized Controlled Trial

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

Clinical Trial

Published on 2021-05-012022-10-05
Journal: Stem cells translational medicine [Category] SARS, 임상, 진단,

[키워드] 1:1 24 hour acute respiratory distress AEs analyzed anti-inflammatory effect ARDS Cell cell transplantation cellular cellular therapy clinical trials Control control group COVID-19 cytokine death determine distress double-blind Effect Efficacy Endpoint event group groups high mortality immunomodulatory improved patient survival intention to treat intravenous infusion mesenchymal stem cell Mesenchymal stem cells patient survival Randomized Randomized controlled trial randomized, controlled trial respiratory tract SAEs Safe secondary Serious Adverse Event severity significantly Standard of care stem cell Stratification subject survival syndrome Time to recovery transplantation Treatment treatment group UC-MSC umbilical Umbilical cord was performed was used with COVID-19
[DOI] 10.1002/sctm.20-0472 PMC 바로가기 [Article Type] Clinical Trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

비활성화된 SARS-CoV-2 백신 BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 1상 시험

Clinical Trial

Published on 2021-05-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI Administered adverse event Adverse reactions alum assigned baseline Bharat block Block randomisation CD4 CD8 Cell-mediated responses control group control vaccine COVID-19 doses double-blind Effect Efficacy eligible ELISPOT enrolled evaluated event fatigue Fever first dose groups headache healthy hospital immune responses immunogenicity inactivated India individual injection site pain intramuscular dose investigator investigators Local Mild mitigate moderate multicentre nausea neutralisation nine nucleic acid outcome participant Participants Phase 1 phase 1 trial Phase 2 platform Pneumonitis positive Primary outcomes randomisation randomised Randomly receive Registered reported response Safety SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened secondary secondary outcome selected Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rates serology test serology tests Seven staining study duration subset systemic adverse reaction systemic adverse reactions systemic reactogenicity T-cell Response T-cell responses the vaccine tolerable Toll-like receptor treatment group Trial trials vaccination Vaccine Viral vomiting was done were excluded wild-type virus
[DOI] 10.1016/S1473-3099(20)30942-7 PMC 바로가기 [Article Type] Clinical Trial

Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine

Endocrinology/Diabetes/Metabolism

Published on 2021-04-282022-10-31
Journal: Cureus [Category] COVID-19,

Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic

팬데믹 초기 단계에서 COVID-19 감염 치료를 받은 환자의 심장 교정 QT 간격 변화

Research

Published on 2021-04-232022-09-12
Journal: JAMA Network Open [Category] MERS, SARS, 진단,

[키워드] 12-lead electrocardiogram 95% CI age Analysis analyzed association Azithromycin baseline Black patients cardiac center change Chronic kidney disease clinical factor cohort study Columbia University Columbia University Irving Medical Center COVID-19 COVID-19 infection Critical illness ECG ECGs electrocardiogram elevated elevated lactate dehydrogenase evaluate evaluated exposure finding greater had more Hospitalization Hospitalized hospitalized patients Hydroxychloroquine Importance incidence increase in independent independent of Infection infection with COVID-19 Inflammatory response interval Kidney disease Lactate lactate dehydrogenase mean difference measure men multivariable multivariable analysis multivariable model Multivariable models objective observation period occurred Older participant Patient patients with COVID-19 patients without COVID-19 phase Point prolonged corrected QT interval proportion QT interval QTc QTc interval QTC prolongation receiving Relevance Result SARS-CoV-2 SARS-CoV-2 testing setting torsades de pointes treatment group troponin level virus with COVID-19
[DOI] 10.1001/jamanetworkopen.2021.6842 PMC 바로가기 [Article Type] Research

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

Research

Published on 2021-04-222022-10-05
Journal: Nature Medicine [Category] SARS, 임상, 진단,

[키워드] acute respiratory syndrome Adults adverse event Asian BNT162b1 China Chinese clinical investigation convalescent coronavirus COVID-19 domain dose double-blind effective ENCODE event geometric healthy human sera humoral immunogenicity data interferon-γ Jiangsu local reaction Mild moderate mRNA vaccine Neutralizing titer Older pandemic parallel-group participant Participants peptide pool phase 1 study phase 1 trial Placebo placebo-controlled polymerase chain positive prime and boost Randomized RBD reached receive response robust Safety safety profile SARS-CoV-2 single-center spike glycoprotein the RBD the SARS-CoV-2 the vaccine Tolerability treatment group vaccination Vaccine vaccine candidate
[DOI] 10.1038/s41591-021-01330-9 [Article Type] Research

Giloy Ghanvati ( Tinospora cordifolia (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish

Pharmacology

Published on 2021-04-192022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] A549 artificial ventilation ayurved Ayurveda caused changes in comparable correlated cough disease disease phenotype distress dosage epithelial cell feature Fever giloy ghanvati granulocyte healthcare Hook human lung humanized Immune cell induced Infection infiltration inflamation Inflammation lack Macrophage Model phenotype pro-inflammatory renal tissue reported respiratory reversed SARS-CoV-2 SARS–CoV–2 spike-protein swim bladder symptomatic systemic damage targeted therapy the disease the SARS-CoV-2 therapy tinopsora cordifolia Traditional Treatment treatment group viral disease were given xenotranplantation zebrafish
[DOI] 10.3389/fphar.2021.635510 PMC 바로가기 [Article Type] Pharmacology